Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
CEPHEUS
1 other identifier
observational
1,000
1 country
8
Brief Summary
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2010
Shorter than P25 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 14, 2010
CompletedFirst Posted
Study publicly available on registry
October 15, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedMarch 1, 2012
February 1, 2012
5 months
October 14, 2010
February 29, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines
1 visit - 1-3 days
Secondary Outcomes (3)
Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome
1 visit - 1-3 days
Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome
1 visit - 1-3 days
Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides >200 mg/dL (2.26mmol/L)
1 visit - 1-3 days
Study Arms (1)
1
Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
Eligibility Criteria
Subject on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
You may qualify if:
- Subject must be 18 years of age or older of either gender or race.
- Subject must provide informed consent and comply with the survey procedures.
- Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
You may not qualify if:
- Subjects who are unwilling or unable to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (8)
Research Site
Krasnodar, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Novosibirsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Samara, Russia
Research Site
Voronezh, Russia
Research Site
Yaroslavl, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Alexey Stepanov, Prof
AstraZeneca
- PRINCIPAL INVESTIGATOR
Prof. Boytsov
RKNPK
- PRINCIPAL INVESTIGATOR
Acad Oganov
Center of preventive medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 14, 2010
First Posted
October 15, 2010
Study Start
October 1, 2010
Primary Completion
March 1, 2011
Study Completion
March 1, 2011
Last Updated
March 1, 2012
Record last verified: 2012-02